Metabolic disease in HIV infection

The Lancet Infectious Diseases

Volumn 13, Issue 11, 2013, Pages 964-975

  Lake, Jordan E ^a   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DARUNAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCOSE; INSULIN; LEFLUNOMIDE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE;

ADIPOSE TISSUE; ANTIVIRAL THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; METABOLIC DISORDER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADIPOSE TISSUE; ANTI-HIV AGENTS; HIV; HIV INFECTIONS; HUMANS; METABOLIC DISEASES;

EID: 84886931574     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70271-8     Document Type: Review

References (142)

1. Bereziat V, Cervera P, Le Dour C, et al. LMNA mutations induce a non-inflammatory fibrosis and a brown fat-like dystrophy of enlarged cervical adipose tissue. Am J Pathol 2011, 179:2443-2453.
2. Torriani M, Fitch K, Stavrou E, et al. Deiodinase 2 expression is increased in dorsocervical fat of patients with HIV-associated lipohypertrophy syndrome. J Clin Endocrinol Metab 2012, 97:e602-e607.
3. Kosmiski LA, Sage-El A, Kealey EH, Bessesen DH Brown fat activity is not apparent in subjects with HIV lipodystrophy and increased resting energy expenditure. Obesity (Silver Spring) 2011, 19:2096-2098.
4. Torriani M, Zanni MV, Fitch K, et al. Increased FDG uptake in association with reduced extremity fat in HIV patients. Antivir Ther 2013, 18:243-248.
5. Sevastianova K, Sutinen J, Greco D, et al. Comparison of dorsocervical with abdominal subcutaneous adipose tissue in patients with and without antiretroviral therapy-associated lipodystrophy. Diabetes 2011, 60:1894-1900.
6. Garrabou G, Lopez S, Moren C, et al. Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS 2011, 25:165-170.
7. Vidal F, Domingo P, Villarroya F, et al. Adipogenic/lipid, inflammatory, and mitochondrial parameters in subcutaneous adipose tissue of untreated HIV-1-infected long-term nonprogressors: significant alterations despite low viral burden. J Acquir Immune Defic Syndr 2012, 61:131-137.
8. Feeney ER, van Vonderen MG, Wit F, et al. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA. AIDS 2012, 26:2165-2174.
9. McComsey GA, Daar ES, O'Riordan M, et al. Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. J Infect Dis 2013, 207:604-611.
10. Gallego-Escuredo JM, Villarroya J, Domingo P, et al. Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy. J Acquir Immune Defic Syndr 2013, published online May 24. 10.1097/QAI.0b013e31829bdb67.
11. McGee KC, Shahmanesh M, Boothby M, et al. Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones. Antivir Ther 2012, 17:495-507.
12. Morse CG, Voss JG, Rakocevic G, et al. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis 2012, 205:1778-1787.
13. Giralt M, Domingo P, Villarroya F Adipose tissue biology and HIV-infection. Best Pract Res Clin Endocrinol Metab 2011, 25:487-499.
14. Lake JE, Currier JS Switching antiretroviral therapy to minimize metabolic complications. HIV Ther 2010, 4:693-711.
15. Martin A, Amin J, Emery S, et al. Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 2011, 6:e26885.
16. de Waal R, Cohen K, Maartens G Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013, 8:e63623.
17. McComsey GA, O'Riordan M, Choi J, et al. Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir. Antivir Ther 2012, 17:347-353.
18. Schlapfer E, Fischer M, Ott P, Speck RF Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea. AIDS 2003, 17:1613-1620.
19. Mencarelli A, Francisci D, Renga B, et al. Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-gamma-dependent manner. Antivir Ther 2012, 17:669-678.
20. Read SW, DeGrezia M, Ciccone EJ, et al. The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS One 2010, 5:e11937.
21. Shuck J, Iorio ML, Hung R, Davison SP Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes. Plast Reconstr Surg 2013, 131:499-506.
22. Nadarajah JT, Collins M, Raboud J, et al. Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy. Clin Infect Dis 2012, 55:1568-1574.
23. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011, 53:185-196.
24. Minami R, Yamamoto M, Takahama S, Ando H, Miyamura T, Suematsu E Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. J Infect Chemother 2011, 17:183-188.
25. Capel E, Auclair M, Caron-Debarle M, Capeau J Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes. Antivir Ther 2012, 17:549-556.
26. Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells. J Infect Chemother 2012, 18:485-493.
27. Gibellini L, De Biasi S, Pinti M, et al. The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes. AIDS 2012, 26:2017-2026.
28. Diaz-Delfin J, Domingo P, Mateo MG, et al. Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antimicrob Agents Chemother 2012, 56:3369-3375.
29. Diaz-Delfin J, del Mar Gutierrez M, Gallego-Escuredo JM, et al. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res 2011, 91:112-119.
30. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011, 53:807-816.
31. Reynes J, Trinh R, Pulido F, Soto-Malave R, et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 2013, 29:256-265.
32. Lake JE, McComsey GA, Hulgan TM, et al. A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS 2012, 26:532-540.
33. Ofotokun I, Sheth AN, Sanford SE, et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses 2012, 28:1196-1206.
34. Curran ASM, Martinez E, Larrouse M, et al. Body composition changes after switching from protease inhibitors to RAL: SPIRAL LIP substudy. AIDS 2012, 26:475-481. SPIRAL Study Group.
35. Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA Neutral actions of Raltegravir on adipogenesis, glucose metabolism and lipolysis in 3T3-L1 adipocytes. Curr HIV Res 2011, 9:174-179.
36. Diaz-Delfin J, Domingo P, Giralt M, Villarroya F Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine 2013, 61:808-815.
37. Glesby MJ, Albu J, Chiu YL, et al. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One 2013, 8:e61160.
38. Falutz J Growth hormone and HIV infection: contribution to disease manifestations and clinical implications. Best Pract Res Clin Endocrinol Metab 2011, 25:517-529.
39. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis 2012, 54:1642-1651.
40. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363:1346-1353.
41. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2004, 286:e296-e303.
42. Jain S, Desai N, Bhangoo A Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. Rev Endocr Metab Disord 2013, 14:113-118.
43. Sinha U, Sinharay K, Sengupta N, Mukhopadhyay P Benefits of leptin therapy in HIV patients. Indian J Endocrinol Metab 2012, 16(suppl 3):S637-S643.
44. Paruthi J, Gill N, Mantzoros CS Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism 2013, 62:1199-1205.
45. Lee JH, Chan JL, Sourlas E, Raptopoulos V, Mantzoros CS Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006, 91:2605-2611.
46. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009, 94:1137-1144.
47. Brown TT, Chen Y, Currier JS, et al. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013, 63:323-330.
48. Lake JE, Tseng CH, Currier JS A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. PLoS One 2013, 8:e58135.
49. Malaza A, Mossong J, Barnighausen T, Newell ML Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. PLoS One 2012, 7:e47761.
50. Kim DJ, Westfall AO, Chamot E, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012, 61:600-605.
51. Kroll AF, Sprinz E, Leal SC, Labrea Mda G, Setubal S Prevalence of obesity and cardiovascular risk in patients with HIV/AIDS in Porto Alegre, Brazil. Arq Bras Endocrinol Metabol 2012, 56:137-141.
52. Isasti G, Perez I, Moreno T, Cabrera F, Palacios R, Santos J Echocardiographic abnormalities and associated factors in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses 2013, 29:20-24.
53. Tate T, Willig AL, Willig JH, et al. HIV infection and obesity: where did all the wasting go?. Antivir Ther 2012, 17:1281-1289.
54. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005, 6:114-121.
55. Brar I, Shuter J, Thomas A, Daniels E, Absalon J A comparison of factors associated with prevalent diabetes mellitus among HIV-Infected antiretroviral-naive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007, 45:66-71.
56. Samaras K The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care. Curr HIV/AIDS Rep 2012, 9:206-217.
57. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130-139.
58. Blass SC, Ellinger S, Vogel M, et al. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism-a reason for glycemic control. Eur J Med Res 2008, 13:209-214.
59. Kosmiski LA, Scherzer R, Heymsfield SB, et al. Association of increased upper trunk and decreased leg fat with 2-h glucose in control and HIV-infected persons. Diabetes Care 2011, 34:2448-2453.
60. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008, 31:1224-1229.
61. Capeau J, Bouteloup V, Katlama C, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS 2012, 26:303-314.
62. Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003, 32:298-302.
63. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007, 21:1739-1745.
64. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165:1179-1184.
65. Veloso S, Escote X, Ceperuelo-Mallafre V, et al. Leptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophy. Cytokine 2012, 58:253-260.
66. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003, 17:1503-1511.
67. Sweeney LL, Brennan AM, Mantzoros CS The role of adipokines in relation to HIV lipodystrophy. AIDS 2007, 21:895-904.
68. Hruz PW Molecular mechanisms for insulin resistance in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011, 25:459-468.
69. Gallego-Escuredo JM, Domingo P, Gutiérrez MM, et al. Reduced levels of serum FGF19 and impaired expression of receptors for endocrine FGFs in adipose tissue from HIV-infected patients. J Acquir Immune Defic Syndr 2012, 61:527-534.
70. Paik IJ, Kotler DP The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011, 25:469-478.
71. Kalra S, Kalra B, Agrawal N, Unnikrishnan A Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr 2011, 3:2.
72. Rojas LB, Gomes MB Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013, 5:6.
73. Sheth SH, Larson RJ The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. BMC Infect Dis 2010, 10:183.
74. van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337-346.
75. Fitch K, Abbara S, Lee H, et al. Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS 2012, 26:587-597.
76. Evans JM, Ogston SA, Emslie-Smith A, Morris AD Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006, 49:930-936.
77. Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D PPAR- gamma agonist in treatment of diabetes: cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem 2012, 10:124-134.
78. Mondal D, Liu K, Hamblin M, Lasky JA, Agrawal KC Nelfinavir suppresses insulin signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J 2013, 13:76-90.
79. Tungsiripat M, El-Bejjani D, Rizk N, et al. Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses 2011, 27:295-302.
80. van Wijk JP, Hoepelman AI, de Koning EJ, Dallinga-Thie G, Rabelink TJ, Cabezas MC Differential effects of rosiglitazone and metformin on postprandial lipemia in patients with HIV-lipodystrophy. Arterioscler Thromb Vasc Biol 2011, 31:228-233.
81. Oriot P, Hermans MP, Selvais P, Buysschaert M, de la Tribonniere X Exenatide improves weight loss insulin sensitivity and beta-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Ann Endocrinol (Paris) 2011, 72:244-246.
82. Gadsby R Efficacy and safety of sitagliptin in the treatment of type 2 diabetes. Clin Med Ther 2009, 1:53-62.
83. Goodwin SR, Reeds DN, Royal M, Struthers H, Laciny E, Yarasheski KE Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study. J Clin Endocrinol Metab 2013, 98:743-751.
84. Nachega JB, Hsu AJ, Uthman OA, Spinewine A, Pham PA Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. AIDS 2012, 26(suppl 1):S39-S53.
85. Mastan S, Kumar KE Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetol Metab Syndr 2009, 1:15.
86. Magkos F, Brennan A, Sweeney L, et al. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. Metabolism 2011, 60:1045-1049.
87. Escote X, Megia A, Lopez-Dupla M, et al. A study of fatty acid binding protein 4 in HIV-1 infection and in combination antiretroviral therapy-related metabolic disturbances and lipodystrophy. HIV Med 2011, 12:428-437.
88. Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007, 8:280-287.
89. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011, 154:445-456.
90. Ganesan A, Benning L, Golub ET, et al. Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens. AIDS Res Ther 2009, 6:13.
91. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009, 23:1679-1688.
92. Ucciferri C, Falasca K, Vignale F, Di Nicola M, Pizzigallo E, Vecchiet J Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol 2013, 85:755-759.
93. Aberg JA, Tebas P, Overton ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012, 28:1184-1195.
94. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 2013, 63:77-85.
95. Ongoing safety review of abacavir, possible MI risk. AIDS Alert 2011, 26:58-59. No authors listed: FDA notifications.
96. STRIBILD prescribing information Gilead Science, Inc., (accessed Sept 26, 2013). http://services.gileadhiv.com/stribild/pdf/pi.
97. Rockstroh JK, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013, 62:483-486.
98. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012, 379:2439-2448.
99. Elion R, Molina JM, Ramon Arribas Lopez J, et al. A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results. J Acquir Immune Defic Syndr 2013, 63:494-497.
100. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012, 12:111-118.
101. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013, 381:735-743.
102. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378:238-246.
103. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378:229-237.
104. MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials 2011, 12:24-36.
105. Crane HM, Grunfeld C, Willig JH, et al. Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011, 25:185-195.
106. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011, 204:1191-1201.
107. Behrens G, Maserati R, Rieger A, et al. Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles. Antivir Ther 2012, 17:1011-1020.
108. Campo R, DeJesus E, Bredeek UF, et al. SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. Clin Infect Dis 2013, 56:1637-1645.
109. Saumoy M, Ordonez-Llanos J, Martinez E, et al. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther 2011, 16:459-468.
110. Martinez E, d'Albuquerque PM, Perez I, Pich J, Gatell JM Abacavir/lamivudine versus tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS Res Hum Retroviruses 2013, 29:235-241.
111. Rhoads MP, Lanigan J, Smith CJ, Lyall EG Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr 2011, 57:404-412.
112. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012, 60:369-376.
113. Dube MP, Cadden JJ Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab 2011, 25:429-442.
114. Wooten JS, Nambi P, Gillard BK, et al. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. Med Sci Sports Exerc 2013, 45:1043-1050.
115. Stradling C, Chen YF, Russell T, Connock M, Thomas GN, Taheri S The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis. PLoS One 2012, 7:e38121.
116. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
117. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008, 9:72-81.
118. Ahmed MH, Al-Atta A, Hamad MA The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. Expert Opin Pharmacother 2012, 13:1901-1909.
119. Sponseller C, Morgan R, Campbell S, et al. Pitavastatin 4 mg provides greater LDL-C reduction compared to pravastatin 40 mg over 12 weeks of treatment in HIV-infected adults with dyslipidemia. 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, GA, USA; March 3-6, 2013. 187LB.
120. Lichtenstein KA, Armon C, Buchacz K, et al. Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chronic Dis 2013, 10:e10.
121. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010, 375:396-407.
122. Martinez E, D'Albuquerque PM, Llibre JM, et al. Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir. AIDS 2012, 26:2315-2326.
123. Gupta SK, Shen C, Moe SM, Kamendulis LM, Goldman M, Dube MP Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One 2012, 7:e45716.
124. Shikuma CM, Ribaudo HJ, Zheng Y, et al. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses 2011, 27:461-468.
125. McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS 2012, 26:1371-1385.
126. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010, 201:318-330.
127. Monforte A, Reiss P, Ryom L, et al. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS 2013, 27:407-415.
128. Triant VA HIV infection and coronary heart disease: an intersection of epidemics. J Infect Dis 2012, 205(suppl 3):S355-S361.
129. Sims A, Hadigan C Cardiovascular complications in children with HIV infection. Curr HIV/AIDS Rep 2011, 8:209-214.
130. Rotger M, Glass TR, Junier T, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clin Infect Dis 2013, 57:112-121.
131. Triant VA, Meigs JB, Grinspoon SK Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009, 51:268-273.
132. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
133. Triant VA, Meigs JB, Grinspoon SK Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009, 51:268-273.
134. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011, 203:780-790.
135. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011, 204:1227-1236.
136. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012, 308:379-386.
137. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012, 206:1558-1567.
138. Blodget E, Shen C, Aldrovandi G, et al. Relationship between microbial translocation and endothelial function in HIV infected patients. PLoS One 2012, 7:e42624.
139. Crowe SM, Hoy JF Are monocytes the canary in the coal mine for HIV-related atherosclerosis?. J Infect Dis 2012, 206:1491-1493.
140. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012, 7:e44454.
141. Hileman CO, Longenecker CT, Carman TL, et al. Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther 2012, 17:13454-13459.
142. Kaplan RC, Landay AL, Hodis HN, et al. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr 2012, 60:359-368.